INVESTOR PRESENTATION November 2015 Disclaimer This presentation - PowerPoint PPT Presentation

INVESTOR PRESENTATION November 2015

Disclaimer This presentation contains statements that constitute “forward looking statements” including and without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. While these forward looking statements represent our judgment and future expectations concerning the development of our business, a number of risks, uncertainties and other important factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macro-economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that we have indicated could adversely affect our business and financial performance. Aurobindo Pharma undertakes no obligation to publicly revise any forward looking statements to reflect future events or circumstances. For updates and specific queries, please visit our website www. aurobindo.com 1

Global Pharmaceutical Industry Global spending on prescription medicines grew by approximately US$194 billion between 2008 and 2013, and is expected to reach size of c.US$1.3 trillion in 2018 Contribution to Growth Geographic Distribution of Medical Spending 2013 2018 2013-18 $1,280bn $305bn - $989bn - $1,310bn $335bn North America remains the largest pharmaceutical market with US representing one third of global total spending Industry growth has been fueled by increase in prices and implementation of Affordable Care Act resulting in expanded healthcare access European generic drugs market represents the second-largest regulated market for generic drugs Majority of European markets’ growth is expected to remain flat and be largely influenced by changes to discounts and price c uts Emerging markets have been rising boosted by a combination of rapid population growth and improved access to subsidized healthcare Growth will be largely driven by generic and non-branded products; spending on generics expected to grow at a double that of branded generics Source: IMS, Global Outlook for Medicines Through 2018, November 2014 2

Company Overview Net Operating Income (INR Mn) Among the Top-5 listed pharmaceutical companies from India by sales (1) and market capitalisation (2) A global company with more than 85% of operating income coming from international operations, spanning across 150+ countries Strategic advantage via vertical integration with in-house API for a major proportion of its products Well entrenched position in the US with 382 filed ANDAs Q2 FY16 Sales by Segment (%) and 168 pending approval (2) One of the leading Indian pharmaceutical companies with strong generics footprint in Europe Increasing focus on complex molecules, differentiated technology platforms and specialty products 1) As of 31 March 2015; 2) As on 30 Sept 2015 3

The Journey So Far… Creation of a leading vertically integrated platform  Acquired formulations  Commencement of export  Acquired Western European  First approval of Controlled facility in USA and of APIs commercial operations from Actavis Substance formulations in Pharmacin in Netherlands and Natrol, US nutraceuticals  Initial Public Offering USA  Investment in building company (1995)  Set up AuroPeptide to manufacturing, marketing  Focus on differentiated technology  Began production of foray into Peptide business & IPR capabilities platforms eg. depot injections formulations 1992 – 2002 2006 2007 2010 2012 2013 2014 2015  Commenced operations of  Commenced marketing  Investment into Tergene  Acquired UK based SEZ Unit VII and Aurolife, specialty injectables to fund the development Milpharm USA facilities and divested products in USA through of a pneumonia vaccine Chinese antibiotics facility AuroMedics  Building capabilities in Penem, Oncolytics & Bio- catalysis Foray into Consolidating Presence in Finished Establishing Global US and EU + Expanding API Focus Dosage Footprint Injectables & Differentiated Formulations Offerings 4

Key Business Segments Formulations APIs US EU ARV and RoW  ARV – Institutional  Portfolio of 382 ANDA  Focus markets  Strategically filings including 214 are France, important business  Focus on selective – also serves as approved ANDAs Germany, participation in global Netherlands, captive source for tenders  Incrementally Spain, UK, Italy FDF products  Cost effective generic differentiated and Portugal versions of over 43 ARV pipeline with new  One of the leading products distributed launches including  Augmented supplier of APIs across more than 100 injectables, position via from India - serves countries ophthalmics , acquisition of as a source for Overview speciality products,  RoW Generics commercial various Gx and controlled infrastructure and  Focus markets with branded drugs substances and pipeline from ground presence nutraceuticals  Strong regulatory Actavis in seven include Mexico, capability with 200 Western Colombia, Brazil, Russia,  Manufacturing and US DMF filings European Canada, South Africa and R&D presence in the countries Middle East US including  Expansion in new controlled substances markets through ground and Depot injections presence / partnerships H1 FY15-16 5

US Generics AuroLife Pharma Aurobindo USA AuroMedics AuroHealth Natrol Manufacturing / Oral Rx Injectables Pharma OTC Nutraceuticals R&D Cumulative ANDA Filings and Approvals* Gross Sales (INR Mn)  Broad product portfolio mix complemented with the introduction Unit wise ANDA Filings as at 30-Sept-2015 Filed Approved Under Review of high value paroducts 117 112 5 Unit III NPNC Oral 66 15 51 Unit IV NPNC Injectables  Strong Pipeline of injectable products 11 11 0 Unit VIB Cephelosporin Oral incl. ophthalmic, respiratory, 141 47 94 Unit VII (SEZ) NPNC Oral oncolytic, hormones and penems 19 19 0 Unit XII Penicillin Oral & Injectables 26 10 16 Aurolife USA NPNC / Controlled Substances Oral  Foray into Pharma OTC and 2 0 2 AuroNext Penem Injectables Branded Nutraceuticals Total 382 214 168 6 *Tentative Approvals include 21 ANDAs approved under PEPFAR, which are not for commercialization in the US market

EU Generics United France Germany Netherlands Spain Italy Portugal Kingdom Gross Sales (INR Mn)  One of the leading Indian companies with strong generics footprint in Europe. Presence in Rx, TGx, BGx, Hx and OTC  Foray into EU markets via acquisition of and integrating commercial operations of Milpharm in UK and Pharmacin in Netherlands  Expanded presence through acquisition of Actavis assets in 2014; acquired product lines and distribution network incl. 1,250 dossier license rights Critical Mass through Acquisition of Commercial Assets in Western Europe from Actavis Acquired Platform Aurobindo Contribution Opportunity to Leverage  Commercial Infrastructure in  Cost effective high quality  Achieve critical mass with top 10 rank in several key APIs 7 countries markets in Europe − 1,200 products with more than 450  Large integrated  Leveraging its vertically integrated platform and ability to INNs manufacturing capabilities source lower cost API to materially lower COGS − Pipeline of over 200 products  Good presence in Injectables  Significant number of molecules to be site transferred or −‘ Arrow Génériques ’ brand market replaced by Aurobindo manufactured product − Dossier licenses  Broadbase product portfolio to  Compliment acquired hospital sales infrastructure with − Readymade hospital sales better utilize marketing injectable and specialty portfolio across Western Europe infrastructure registrations including OTC 7

ARV TGx and RoW Generics ARV-Overview Gross Sales (INR Mn)  Globally 35 million people are HIV+ infected with only 12 million receiving treatment  Focus on selective participation in global tenders (PEPFAR, Clinton Foundation / WHO, Country specific); currently caters to 2.2 million HIV+ patients  Cost effective generic versions of over 43 ARV product catering to more than 100 countries  Well integrated supply chain management services and logistics for ARV supplies  Conducts regular medical education programs to ensure education on proper use of medicines for HIV/AIDS RoW Gx-Overview  Focus markets include Brazil, South Africa, Canada, Russia, Mexico, Middle East; expansion ongoing in new markets through ground presence/partnerships  Rising healthcare costs, capacity constraints and growing economic disparities pose new challenges and provide opportunities to promote Gx. 8